Breaking Finance News

Inovio Pharmaceuticals Inc (NASDAQ:INO) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Boasting a price of $9.46, Inovio Pharmaceuticals Inc (NASDAQ:INO) traded -0.21% lower on the day. With the last close up 0.89% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Inovio Pharmaceuticals Inc has recorded a 50-day average of $9.10 and a two hundred day average of $9.40. Volume of trade was down over the average, with 514,057 shares of INO changing hands under the typical 1,352,340

Zacks Investment Research has upgraded Inovio Pharmaceuticals Inc (NASDAQ:INO) to Hold in a statement released on 09/26/2016.

Performance Chart

Inovio Pharmaceuticals Inc (NASDAQ:INO)

With a total market value of $0, Inovio Pharmaceuticals Inc has with a one year low of $4.50 and a one year high of $11.69 .

A total of 5 analysts have released a research note on INO. Two analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $18.60.

More About Inovio Pharmaceuticals Inc (NASDAQ:INO)

Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *